2022
Alloimmunization following antigen‐negative red blood cell transfusion
Jacobs J, Binns T, Abels E, Iyer K, Villalba C, Verma A, Sostin N, Tormey C. Alloimmunization following antigen‐negative red blood cell transfusion. Transfusion 2022, 63: 430-434. PMID: 36458330, DOI: 10.1111/trf.17208.Peer-Reviewed Case Reports and Technical NotesConceptsTransfusion of RBCsRed blood cell transfusionRed blood cell alloimmunizationPrevious antigen exposureBlood cell transfusionAlloantibody specificitiesCell transfusionRBC transfusionAntigen exposureRBC alloantibodiesAntigenic stimulusDetectable titersAntigenic stimulationMyeloid neoplasmsTransfusionAlloantibodiesAlloimmunizationParticular antigenPrior exposureStimulatory eventsExact mechanismCorresponding antibodiesRBCsExposurePregnancy
2020
Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn
Gupta GK, Balbuena-Merle R, Hendrickson JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion And Apheresis Science 2020, 59: 102946. PMID: 32962917, DOI: 10.1016/j.transci.2020.102946.Peer-Reviewed Original ResearchConceptsRed blood cellsHemolytic diseaseCurrent pathophysiologic mechanismsSetting of pregnancyPeri-partum periodPregnant patientsRBC alloantibodiesPathophysiologic mechanismsTransfusion practiceAlloantibody detectionTransfusion therapyClinical impactAlloimmunizationTransfusion communityBlood bankPregnancyDeadliest formBlood cellsAlloantibodiesFetusesDiseaseLaboratory toolPatientsTherapySettingCharacterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status
Balbuena-Merle R, Santhanakrishnan M, Devine L, Gibb DR, Tormey CA, Siddon AJ, Curtis SA, Gallagher PG, Weinstein JS, Hendrickson JE. Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfusion And Apheresis Science 2020, 59: 102778. PMID: 32439490, PMCID: PMC7483805, DOI: 10.1016/j.transci.2020.102778.Peer-Reviewed Original ResearchConceptsTfh-like cellsNaïve CD4 T cellsSickle cell diseaseCD4 T cellsCD4 T cell subsetsT cell subsetsT cellsCell diseaseRed blood cell alloimmunizationPeripheral blood mononuclear cellsBlood mononuclear cellsCD3/CD28Electronic medical recordsAlloimmunization statusHLA alloantibodiesRBC autoantibodiesRBC alloantibodiesFollicular helperIL-12Mononuclear cellsMedical recordsIL-7Antigen specificityB cellsAlloantibodiesThe evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2019
The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors
Balbuena-Merle R, Hauser R, Karafin M, Tan S, Spencer B, Roubinian N, Wu Y, Triulzi D, Kleinman S, Gottschall J, Tormey C, Hendrickson J. The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors. Blood 2019, 134: 2452. DOI: 10.1182/blood-2019-121388.Peer-Reviewed Original ResearchRBC alloantibodiesTransfusion historyBlood donorsBlood donor databasePregnant femalesPersistent antibodiesPrior transfusionsPrior pregnancyAntibody screenMean durationPregnancy historyFemale healthy blood donorsRed blood cell alloantibodiesDonor databaseMean timeAntibody screen resultsHealthy blood donorsUS blood centersSubsequent donationsMajority of donorsSubsequent blood donationsAlloantibody specificitiesRBC alloimmunizationCell microchimerismAntigen exposureRed blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionRespondersTransfusion-related red blood cell alloantibodies: induction and consequences
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood 2019, 133: 1821-1830. PMID: 30808636, PMCID: PMC6484385, DOI: 10.1182/blood-2018-08-833962.Peer-Reviewed Original ResearchConceptsTransfusion recipientsBlood donorsPreventative strategiesBlood product exposureCompatible RBC unitsRBC alloantibody formationHemolytic transfusion reactionsDevelopment of alloantibodiesAdaptive immune factorsJudicious transfusionRBC alloimmunizationImmunomodulatory therapyAlloantibody formationBlood transfusionRBC alloantibodiesRecipient variablesFuture pregnanciesImmune factorsTransfusion reactionsBlood productsHemolytic diseaseFuture transfusionsHuman studiesTransfusionAlloantibodies
2018
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2018, 59: 217-225. PMID: 30427537, DOI: 10.1111/trf.15004.Peer-Reviewed Original ResearchConceptsPositive antibody screenDonor Evaluation Study-IIIAntibody screenRisk factorsRecipient EpidemiologyTransfusion historyBlood centersRBC alloantibodiesBlood donorsRed blood cell alloimmunizationCommon antibody specificitiesPrior transfusion historyRBC alloantibody formationSignificant RBC alloantibodiesHistory of transfusionAdjusted odds ratioMultivariable logistic regressionUS blood centersStudy IIIUS blood donorsPotent immune stimulusFuture medical careHealthy US blood donorsPrior transfusionsPrior pregnancyRisk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Hendrickson JE, Study‐III N. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database. British Journal Of Haematology 2018, 181: 672-681. PMID: 29675950, PMCID: PMC5991618, DOI: 10.1111/bjh.15182.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnemia, Sickle CellArthritis, RheumatoidBlood DonorsBlood Group AntigensChildChild, PreschoolDatabases, FactualErythrocyte TransfusionFemaleHumansImmunizationInfantIsoantibodiesLupus Erythematosus, SystemicMaleMiddle AgedMyelodysplastic SyndromesRisk FactorsTransfusion ReactionConceptsRed blood cell alloimmunizationRecipient EpidemiologyRecipients databaseSignificant RBC alloantibodiesNegative antibody screenLargest RBCStandardized registryPositive patientsRBC alloantibodiesAntibody screenICD9/10 codesPatient cohortRisk factorsResponder statusCertain diagnosisBlood typeLarger studyAlloimmunizationRhD statusStudy databaseRespondersPatientsDisease associationsPotential correlatesEpidemiology
2016
Understanding red blood cell alloimmunization triggers
Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology 2016, 2016: 446-451. PMID: 27913514, PMCID: PMC6142457, DOI: 10.1182/asheducation-2016.1.446.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRed blood cellsRisk factorsBlood cellsWhite blood cellsBlood group antigensPregnancy outcomesAlloantibody formationRBC alloantibodiesRBC transfusionRecipient factorsTransfusion safetyAlloimmunizationAnimal modelsHuman studiesPrevention strategiesDonor plasmaDanger signalsParticular antigenGroup antigensAntigenTransfusionPregnancyNonrespondersCellsClinically significant anti‐KEL RBC alloantibodies are transferred by breast milk in a murine model
Santhanakrishnan M, Tormey CA, Natarajan P, Liu J, Hendrickson JE. Clinically significant anti‐KEL RBC alloantibodies are transferred by breast milk in a murine model. Vox Sanguinis 2016, 111: 79-87. PMID: 26950259, PMCID: PMC4938760, DOI: 10.1111/vox.12387.Peer-Reviewed Original ResearchConceptsBreast milkRBC alloantibodiesIgA antibodiesMurine modelHuman KEL glycoproteinSeries of pregnanciesBreast milk transferHuman breast milkWild-type pupsKEL RBCsNursing infantsClinical significanceAlloantibodiesNursing pupsMurine dataTransfusion experimentsMilk transferInfantsPupsTransfusionHuman dataSequelaePregnancyAnemiaPremature clearance
2014
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfusion Medicine And Hemotherapy 2014, 41: 420-429. PMID: 25670929, PMCID: PMC4280450, DOI: 10.1159/000369109.Peer-Reviewed Original ResearchRed blood cellsPatient populationInfluence of ClinicalDevelopment of antibodiesImportant clinical consequencesDiverse patient populationsBlood group antigensRBC alloimmunizationChronic transfusionRBC alloantibodiesHyper respondersClinical circumstancesClinical consequencesAlloimmunizationMedical literatureTransfusionAlloantibodiesGroup antigensRespondersBlood cellsTransfusion medicinePatientsBiological factorsIndividualsPregnancyRed Blood Cell Alloimmunization Mitigation Strategies
Hendrickson JE, Tormey CA, Shaz BH. Red Blood Cell Alloimmunization Mitigation Strategies. Transfusion Medicine Reviews 2014, 28: 137-144. PMID: 24928468, DOI: 10.1016/j.tmrv.2014.04.008.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesRBC alloimmunizationTransfusion reactionsImmune systemRed blood cell alloantibodiesCompatible RBC unitsRBC alloimmunization rateTransfusion-associated morbidityRecipient's immune systemTransfusion-associated deathForms of anemiaAlloimmunization rateAntigen exposureSignificant morbidityTransfusion recipientsHemolytic diseaseAlloantibodiesHuman studiesAnimal studiesDanger signalsAnimal dataMorbidityAlloimmunizationRBC units
2008
Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans
Tormey CA, Fisk J, Stack G. Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008, 48: 2069-2076. PMID: 18631165, DOI: 10.1111/j.1537-2995.2008.01815.x.Peer-Reviewed Original ResearchConceptsRBC alloantibodiesMale military veteransDecade of birthMilitary veteransVA careRed blood cell alloantibodiesVeterans Affairs Medical CenterHospital-based patientsPercent of casesLarge male predominanceRace/ethnicityAlloantibody frequenciesAlloantibody specificitiesFrequent alloantibodiesTransfusion historyMale predominanceD alloimmunizationTransfusion recordsHigh prevalenceMedical CenterAlloantibodiesAntibody developmentAlloimmunizationAntiglobulin phasePrevalence